Abstract 5928: Prevalence of clonal hematopoiesis in neuroendocrine tumor patients prior to lutetium 177 dotatate therapy (Lu177): A prospective trial of 36 patients
Yael Kusne(University of Arizona), Mohamad Bassam Sonbol(WinnMed), Terra Lasho(Mayo Clinic), Jason S. Starr(Jacksonville College), Mrinal M. Patnaik(Mayo Clinic), Tanios Bekaii‐Saab(WinnMed), Zaid Elsabbagh(Johns Hopkins University), Timothy J. Hobday(Mayo Clinic), Rachel A. Eiring(Mayo Clinic), Þorvarður R. Hálfdánarson(Mayo Clinic), Abhishek A. Mangaonkar(Mayo Clinic)
Cited by 0
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
|JAMA Oncology|2019|472
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
|The Lancet. Gastroenterology & hepatology|2021|423
Inherited antithrombin deficiency: a review
|Haemophilia|2008|396